Research
L-Threonine
11 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Evaluation of safe utilization of L-threonine for supplementation in healthy adults: a randomized double blind controlled trial.
Randomized double blind controlled trial evaluating the safety and tolerability of L-threonine supplementation in healthy male adults. Doses of 0, 3, 6, 9, and 12 g/day were tested over 4 weeks. No significant effects on anthropometric, dietary, or biochemical parameters were observed, except for a minor increase in plasma aspartate amino transferase and creatine kinase at 9 g/day. The NOAEL for L-threonine was determined to be 12 g/day.
Influence of L-threonine supplementation on goblet cell numbers, histological structure and antioxidant enzyme activities of laying hens reared in a hot and humid climate.
RCT with 576 Babcock Brown layers to assess the effects of L-threonine supplementation at 0.2% and 0.3% on histological structure, goblet cell numbers, and antioxidant enzyme activities. L-threonine did not affect gut morphology but increased superoxide dismutases (SOD) concentration at 0.2%, suggesting a potential antioxidant function.
Length of Adaptation Has No Effect on the Threonine Requirement Determined in Healthy Young Adult Males Using the Indicator Amino Acid Oxidation Method.
The study used the indicator amino acid oxidation method to determine if different adaptation periods (1, 3, or 7 days) affect the threonine requirement in healthy adult males. The results showed no statistically significant difference in threonine requirements across the different adaptation periods.
Dietary l-threonine supplementation attenuates lipopolysaccharide-induced inflammatory responses and intestinal barrier damage of broiler chickens at an early age.
This study investigated the effects of l-threonine supplementation on growth performance, inflammatory responses, and intestinal barrier function in young broilers challenged with lipopolysaccharide. L-threonine supplementation reversed LPS-induced increases in feed/gain ratio, reduced pro-inflammatory cytokine concentrations, and normalized intestinal barrier function markers.
[Anomaly in the neurotransmitter amino acids in amyotrophic lateral sclerosis: a therapeutic application].
The study explores the therapeutic application of L-threonine in amyotrophic lateral sclerosis (ALS) by reinforcing inhibitory amino acid activity. L-threonine has been shown to improve some symptoms and signs of ALS.
Effect of medroxyprogesterone acetate on the efficiency of an oral protein-rich nutritional support in HIV-infected patients.
RCT examining the effect of medroxyprogesterone on the efficacy of a protein-rich nutritional support in 12 HIV-infected men. All patients increased body weight during the experimental period, with a higher but not significant weight gain in the medroxyprogesterone group. Medroxyprogesterone may improve the efficacy of oral protein-rich nutritional support.
Threonine kinetics in preterm infants fed their mothers' milk or formula with various ratios of whey to casein.
The study examined threonine kinetics in 17 preterm infants fed either their mothers' milk or formula with varying whey-to-casein ratios. Formula-fed infants showed increased threonine intake and plasma concentrations with higher whey content, but had a lower capacity to oxidize threonine compared to breast milk-fed infants.
A double-blind study of L-threonine in patients with spinal spasticity.
Double-blind, placebo-controlled, crossover study of oral L-threonine at 6 g/day in patients with spinal spasticity. Muscle tone was measured using the Ashworth Scale. The trial concluded in favor of L-threonine, showing a modest but definite antispastic effect.
Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study.
Open therapeutic trial with 30 amyotrophic lateral sclerosis patients randomized to receive L-threonine, vitamin B, or carnitine. No statistical differences in clinical assessment score decline were observed, but L-threonine-treated patients reported less frequent respiratory failure.
A double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis.
A 1-year randomized double-blind placebo-controlled trial of L-threonine (2 g daily) in 15 patients with amyotrophic lateral sclerosis (ALS). The decline in functional status in the placebo group was not statistically different from the L-threonine group.
L-threonine in the treatment of spasticity.
Double-blind, crossover RCT of L-threonine in 18 patients with familial spastic paraparesis. L-threonine administration significantly decreased motor impairment and spasticity compared to placebo, although the benefits were not clinically valuable. Plasma and CSF levels of threonine increased, but glycine levels did not change.